reports
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 15,000 shares of the Company’s common stock to one new employee (the “Inducement Gra...
Texas Pacific Land Corp: 1 director
A director at Texas Pacific Land Corp bought 12 shares at 843.760USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulator...
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Co...
89bio to Participate in Upcoming Investor Conferences
89bio to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in the following investor conferences during the month of September: Wells Fargo 2024 Healthcare ConferenceFormat: Fireside ChatDate: Thursday, September 5, 2024Time: 12:45 PM ET H.C. Wainwright 26th Annual Global Investme...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 19,800 shares of the Company’s common stock to two new employees and 350,000 shares o...
89bio Appoints Francis Sarena as Chief Operating Officer
89bio Appoints Francis Sarena as Chief Operating Officer SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, effective August 5, 2024. “We are excited to welcome Francis to our executive team at this pivotal growth phase for 89bio,” said Rohan Palekar, CEO of 89bio. “As we advance our Phase 3 clinical program for peg...
Midland States Bancorp, Inc. Announces Common Stock and Preferred Stoc...
Midland States Bancorp, Inc. Announces Common Stock and Preferred Stock Dividends EFFINGHAM, Ill., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (NASDAQ: MSBI) announced today that its Board of Directors declared a quarterly cash dividend of $0.31 per share of its common stock. The dividend is payable on August 23, 2024 to all shareholders of record as of the close of business on August 16, 2024. The Board of Directors also declared a cash dividend of $0.4844 per depository share on its 7.75% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series A. The divide...
89bio Reports Second Quarter 2024 Financial Results and Corporate Upda...
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates –The Phase 3 ENLIGHTEN-Fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and the Phase 3 ENLIGHTEN-Cirrhosis trial in patients with compensated cirrhosis (F4) are enrolling patients– –Phase 3 ENTRUST trial for patients with severe hypertriglyceridemia (SHTG) continues to enroll patients and topline data is expected in 2025– SAN FRANCISCO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the develo...
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors SAN FRANCISCO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Dr. Charles McWherter to its Board of Directors, effective July 30, 2024. Dr. McWherter most recently served as Chief Scientific Officer and President of Research and Development of CymaBay Therapeutics until it was acquired by Gilead Sciences...
Midland States Bancorp, Inc. Announces 2024 Second Quarter Results
Midland States Bancorp, Inc. Announces 2024 Second Quarter Results Second Quarter 2024 Highlights: Net income available to common shareholders of $4.5 million, or $0.20 per diluted shareAdjusted pre-tax, pre-provision earnings of $25.2 millionTangible book value per share decreased to $23.36, compared to $23.44 at March 31, 2024Common equity tier 1 capital ratio improved to 8.63% from 8.60%Net interest margin of 3.12%, compared to 3.18% in prior quarterEfficiency ratio of 65.2%, compared to 58.0% in prior quarter EFFINGHAM, Ill., July 25, 2024 (GLOBE NEWSWIRE) -- Midland States Bancorp,...
- MarketLine Department
Toromont Industries Ltd - Company Profile and SWOT Analysis
Summary Toromont Industries Ltd - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Toromont Industries Ltd (Toromont) is a company that specializes in the sale, rental, and provision of mobile equipment and industrial engines. The company operates Caterpillar dealerships throu...
- Jeff Robertson
Estimate Update
We are updating our 2Q24 estimates to reflect actual oil and natural gas prices. Our reference oil price averaged $80.66 during 2Q24, and our reference natural gas price averaged $2.33/MMBtu. For 2Q24, we estimate total revenue of $139.1 million based on estimated average production of ~35.0 MBOE/d, including ~14.1 MB/d of oil. Oil accounts for 41% of our production estimate and 76% of our revenue estimate. Our 2Q24 adjusted EBITDA estimate is $36.2 million, compared to $49.4 million in 1Q24 and...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, July 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 125,000 shares of the Company’s common stock to six new employees (the “Inducement Gr...
Midland States Bancorp, Inc. to Announce Second Quarter 2024 Financial...
Midland States Bancorp, Inc. to Announce Second Quarter 2024 Financial Results on Thursday, July 25 EFFINGHAM, Ill., July 05, 2024 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (NASDAQ: MSBI) announced today that it will issue its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Along with the press release announcing the financial results, the Company will publish an investor presentation that will be available on the page of its investor relations website. About Midland State Bancorp, Inc. Midland States Bancorp, Inc. is a community-based financ...
Midland States Bancorp Inc: 2 directors
A director at Midland States Bancorp Inc bought 2,290 shares at 21.800USD and the significance rating of the trade was 40/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, June 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 25,500 shares of the Company’s common stock to two new employees (the “Inducement Gra...
- Jeff Robertson
Recycling Cash Flow in Acquisitions
We hosted a fireside chat with Chairman, President, and CEO Tracy Krohn on March 27, 2024, to discuss the company’s acquisition-driven strategy in the Gulf of Mexico. This report contains a transcript of the conversation, which can be accessed on demand. Link accessible in our full report. Since September 2023, W&T has closed two producing property acquisitions in the Gulf of Mexico for combined cash considerations of ~$104 million. In the most recent closing, the company acquired six shallow-wa...
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial...
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week extension phase of the Phase 2b ENLIVEN trial ...
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in M...
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis —With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval with clinical outcomes to support the potential for confirmatory or full approval— SAN FRANCISCO, May 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clin...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,150 shares of the Company’s common stock to four new employees (the “Inducement Gra...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.